Join
Live feed
·
PRReleasevia Quantisnow
Citius Oncology Inc. logo
Citius Pharmaceuticals Inc. logo

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
CTOR· Citius Oncology Inc.CTXR· Citius Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTOR (Citius Oncology Inc.), CTXR (Citius Pharmaceuticals Inc.) and more on Quantisnow.

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma | Quantisnow